AstraZeneca stops PhIIa trial of inhaled asthma drug with Pieris, cratering the Boston biotech’s shares

After culling a HER2 drug last summer to focus on an inhaled asthma med with AstraZeneca, Pieris Pharmaceuticals appears to be on thin ice with that program as well, as the Big Pharma ended a Phase IIa trial.

Stephen Yoder

AstraZeneca informed Boston-based Pieris yesterday…